Products
Pasotuxizumab Biosimilar Bispecific scFv Antibody (PSMA × CD3) for Research
Pre-Made Pasotuxizumab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pasotuxizumab is a PSMA x CD3 BiTE immune therapy that mediates killing of tumor cells by T cells.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-429-1mg | 1mg | |
| GMP-Bios-ab-429-10mg | 10mg | |
| GMP-Bios-ab-429-100mg | 100mg | |
| GMP-Bios-ab-429-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Pasotuxizumab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody |
| INN Name | Pasotuxizumab |
| Target | GCPII;CD3E |
| Format | Bispecific scFv |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | na |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Amgen;Bayer HealthCare Pharmaceuticals;Micromet Inc |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Prostate cancer |
| Development Tech | na |
About target - FOLH1
1. Protein Glutamate carboxypeptidase 2
2. Gene FOLH1
3. Organism Homo sapiens (Human)
Function
Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of folate. In the brain, modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate. Involved in prostate tumor progression.
Also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.
Miscellaneous
PSMA is used as a diagnostic and prognostic indicator of prostate cancer, and as a possible marker for various neurological disorders such as schizophrenia, Alzheimer disease and Huntington disease.
Catalytic activityi
Release of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates. EC:3.4.17.21
Cofactori
Note: Binds 2 Zn2+ ions per subunit. Required for NAALADase activity.
Activity regulationi
The NAALADase activity is inhibited by beta-NAAG, quisqualic acid, 2-(phosphonomethyl) pentanedioic acid (PMPA) and EDTA. Activated by cobalt.
pH dependencei
Stable at pH greater than 6.5.
